Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Lineage Cell Therapeutics, Inc.

Ticker
LCTX
Sector
Industry
Report date
November 12, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent quarterly reports show Lineage Cell Therapeutics reported losses in Q1, Q2, and Q3 2026, with Q3 revenue below expectations. The company held a Q2 2026 earnings call and maintains analyst coverage with buy recommendations. It reported break-even earnings for Q4 2025.

Recent developments:
  • Lineage Cell reported a loss in Q3 2026 and revenue below expectations [N1].
  • The company held a Q2 2026 earnings call providing operational and financial updates [N2].
  • Lineage Cell reported a loss in Q2 2026 and revenue below expectations [N3].
  • The company reported a loss in Q1 2026 and revenue below expectations [N4].
  • Canaccord Genuity initiated coverage with a buy recommendation in April 2026 [N7].
  • Lineage Cell reported break-even earnings for Q4 2025 [N8].
Overview

Lineage Cell Therapeutics, Inc. develops cell therapy product candidates, supported by government grants and collaboration agreements. The company has financial obligations including royalties, milestone payments, and redemption fees tied to revenues from products developed with grant funding. It operates under leases and contracts with third parties for research and manufacturing services. The company has reported losses in recent quarters but maintains liquidity through cash, marketable securities, and capital raising activities. It is subject to risks related to funding availability, regulatory approvals, and contingent payment obligations.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Lineage Cell Therapeutics, Inc. is a biotechnology company focused on cell therapy development, with ongoing obligations to licensors and government entities related to grants and collaboration agreements. The company reported revenues of $1.434 million and net income of $4.232 million for Q3 2026, with strong liquidity ratios as of September 30, 2026. Recent quarterly results show losses in early 2026 quarters and a Q3 loss with revenue below expectations. The company continues to raise capital through warrant exercises and at-the-market offerings and maintains analyst coverage with buy recommendations.

Scenarios for LCTX

Bull case model:

The company has secured government grants and collaboration agreements that support its research and development efforts. It maintains strong liquidity with cash and marketable securities and has access to capital through warrant exercises and at-the-market offerings. Analyst coverage with buy recommendations reflects positive market interest. The company reported net income in Q3 2026 and break-even earnings in Q4 2025, indicating operational progress.

Bear case model:

Lineage Cell Therapeutics continues to report losses in multiple recent quarters, reflecting ongoing development expenses and operational challenges. Its financial obligations to licensors and government entities are contingent and may fluctuate, creating uncertainty. The company depends on raising additional capital, which may dilute shareholders or require relinquishing rights. Risks include regulatory hurdles, funding availability, and the contingent nature of milestone payments and royalties.

Moat:

Lineage Cell Therapeutics benefits from government grants and collaborations that provide funding and access to intellectual property. Its obligations to licensors and government entities are tied to milestone achievements and royalties, indicating a business model reliant on successful product development and partnerships. The company's specialized cell therapy focus and collaboration agreements may provide competitive advantages in its niche biotechnology sector.

Risks overview
Risks summary
The primary risk is the company's need for additional capital to fund ongoing development and operations, which may lead to dilution or unfavorable financing terms.
Risks details:

• Capital Raising Risk: The company needs significant additional capital to fund operations and may face dilution or unfavorable terms in equity or debt financings.
• Regulatory and Development Risk: Ongoing development and regulatory approval of product candidates involve uncertainties that may impact timelines and costs.
• Contingent Payment Obligations: Payments to licensors and government entities are contingent on milestones and royalties, with uncertain timing and amounts.
• Market and Economic Risks: External factors such as economic conditions, market volatility, and geopolitical events may affect the company's ability to raise capital and operate effectively.

FINAL FORECAST FOR LCTX

Final take one line
Lineage Cell Therapeutics has detailed disclosures and recent earnings reports showing ongoing development with liquidity support but faces risks from continued losses and capital needs.
Final take 12 to 24 month view

Business trends: Continued development of cell therapy candidates with ongoing losses and milestone-based revenue recognition.
Execution milestones: Progress in clinical programs, milestone achievements triggering payments, and capital raising activities.
Key risks: Need for additional capital, regulatory uncertainties, contingent payment obligations, and market volatility impacting funding availability.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Lineage Cell Therapeutics, Inc. is a biotechnology company engaged in research and development of cell therapy product candidates.
  • The company has received government grants under the Innovation Law and is obligated to pay royalties and redemption fees to the Israel Innovation Authority (IIA) based on revenues from products developed with IIA funding, with an aggregate cap of approximately $96.2 million as of December 31, 2025 [S1].
  • Lineage has collaboration agreements, including a Roche Agreement, under which milestone payments and royalties are payable to licensors and government entities, with contingent payment obligations that are not fixed or determinable as of December 31, 2025 [S1].
  • The company operates under leases with total rent payments due of $2.3 million, with $0.9 million due in 2026 [S1].
  • Lineage Cell Therapeutics expects to continue incurring losses for several years and anticipates increasing operating expenses as it develops and seeks regulatory approval for its product candidates [S1].
  • The company raised $5.4 million in gross proceeds from warrant exercises in March 2026 and may receive up to an additional $30.2 million from outstanding warrants; $17.4 million remained available under its at-the-market offering program as of December 31, 2025 [S1].
  • Lineage may seek additional capital through equity offerings, debt financings, grants, strategic alliances, licensing, collaborations, or structured financings, which may involve relinquishing rights or dilution [S1].
  • As of December 31, 2025, Lineage had $55.8 million in cash, cash equivalents, and marketable securities, considered sufficient to fund planned operations for at least twelve months from the issuance date of its consolidated financial statements [S1].
  • The company reported total assets of approximately $112.6 million and total liabilities of approximately $69.2 million as of December 31, 2025, with shareholders' equity of about $43.3 million [S1].
  • Lineage reported revenues of $1.434 million and net income of $4.232 million for the quarter ended September 30, 2026, with basic earnings per share of $0.02 and diluted EPS of -$0.03 [S2].
  • Liquidity ratios as of September 30, 2026, include a current ratio of 5.96 and a cash ratio of 5.63, indicating strong short-term liquidity [S2].
  • Recent quarterly earnings reports indicate the company has reported losses in Q1, Q2, and Q3 of 2026, with Q3 showing a loss and revenue below expectations [N1][N3][N4].
  • Lineage held a Q2 2026 earnings call providing additional operational and financial details [N2].
  • Analyst coverage includes initiation of coverage with a buy recommendation by Canaccord Genuity in April 2026 and maintained buy recommendations by D. Boral Capital and HC Wainwright & Co. in late 2025 [N7].
  • The company reported break-even earnings for Q4 2025 [N8].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-05 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-12 | www.nasdaq.com | Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/lineage-cell-lctx-reports-q3-loss-misses-revenue-estimates
  • N2 | 2026-08-14 | www.nasdaq.com | Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/lineage-cell-therapeutics-lctx-q2-2026-earnings-call-transcript
  • N3 | 2026-08-06 | www.nasdaq.com | Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/lineage-cell-lctx-reports-q2-loss-lags-revenue-estimates
  • N4 | 2026-05-12 | www.nasdaq.com | Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/lineage-cell-lctx-reports-q1-loss-lags-revenue-estimates
  • N5 | 2026-05-11 | www.nasdaq.com | Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/halozyme-therapeutics-halo-surpasses-q1-earnings-and-revenue-estimates
  • N6 | 2026-05-07 | www.nasdaq.com | Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/guardant-health-gh-reports-q1-loss-beats-revenue-estimates
  • N7 | 2026-04-29 | www.nasdaq.com | Canaccord Genuity Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy Recommendation | https://www.nasdaq.com/articles/canaccord-genuity-initiates-coverage-lineage-cell-therapeutics-lctx-buy-recommendation
  • N8 | 2026-03-05 | www.nasdaq.com | Lineage Cell (LCTX) Reports Break-Even Earnings for Q4 | https://www.nasdaq.com/articles/lineage-cell-lctx-reports-break-even-earnings-q4
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine